

Synthesis of New Morphinan Opioids by TBADT-Catalyzed Photochemical Functionalization at the Carbon Skeleton**

Dmitry Gorbachev,^[a, b] Elliot Smith,^[a, b] Stephen P. Argent,^[b] Graham N. Newton,^[a, b] and Hon Wai Lam^{*[a, b]}

Abstract: The synthesis of new morphinan opioids by the addition of photochemically generated carbon-centered radicals to substrates containing an enone in the morphinan C-ring, is described. Using tetrabutylammonium decatungstate (TBADT) as a hydrogen atom transfer photocatalyst, diverse

radical donors can be used to prepare a variety of C8-functionalized morphinan opioids. This work demonstrates the late-stage modification of complex, highly functionalized substrates.

Introduction

Morphinan opioids (Figure 1 shows representative examples), typified by its most well-known member morphine,^[1] are important medicines for the treatment of pain and other disorders because of their effect on the opioid receptors in the central nervous system. However, many opioids possess significant side effects that include respiratory depression, sedation, and constipation. They can be highly addictive, which leads to abuse and significant numbers of overdose deaths.^[1d,e,2] Therefore, there has been a long-standing quest to develop new opioids that retain beneficial therapeutic qualities but with reduced side effects and addictive properties. Extensive research in this area has resulted in the preparation of numerous derivatives, a good understanding of structure-activity relationships (SAR),^[1e,3] and a range of compounds used clinically today.

To date, morphinan opioid SAR studies have investigated the nature of the nitrogen substituent (a methyl group in morphine), which is crucial in determining the biological activity, as well as most regions of the 4,5-epoxymorphinan scaffold.^[3] However, there has been relatively little investigation




Figure 1. Representative morphinan opioids.

of C8-substituted derivatives, which are typically prepared from morphinans containing an enone in the C-ring (see Figure 1 for numbering and labeling).^[4] Kotick and co-workers have reported various functionalizations of morphinan C-ring enones, such as 1,4-additions of organometallic reagents, cyclopropanation, and epoxidation, to prepare a range of C8-substituted derivatives, some of which have interesting biological activities.^[4b-e] A limited number of other reports have described the preparation of C8-substituted derivatives.^[4a,f-j]

The advent of modern methods for the late-stage functionalization^[5] of complex molecules opens up new opportunities to access novel derivatives that previously would have been challenging to prepare, and which could have interesting biological properties. In this context, photochemical hydrogen atom transfer (HAT) catalysis^[6] has recently emerged as a powerful tool for the late-stage functionalization^[5] of complex molecules. Using a HAT photocatalyst, mild and selective C–H functionalization of diverse substrates can be achieved through the generation of carbon-centered radicals, obviating the need for prefunctionalized starting materials.^[6] We questioned whether the 1,4-addition of nucleophilic radicals generated by HAT to morphinan opioids containing an enone in the C-ring would constitute a versatile method to produce C8-substituted derivatives, complementary to those described previously.^[4] To our knowledge, no prior study has focused on this approach, with the only related precedent being the 1,4-addition of photochemically generated THF radicals to two morphinan

[a] D. Gorbachev, E. Smith, Dr. G. N. Newton, Prof. H. W. Lam
The GlaxoSmithKline Carbon Neutral Laboratories for Sustainable Chemistry
University of Nottingham
Jubilee Campus, Triumph Road, Nottingham, NG7 2TU (UK)
E-mail: hon.lam@nottingham.ac.uk
Homepage: <http://www.nottingham.ac.uk/~pczh/>

[b] D. Gorbachev, E. Smith, Dr. S. P. Argent,* Dr. G. N. Newton, Prof. H. W. Lam
School of Chemistry
University of Nottingham
University Park, Nottingham, NG7 2RD (UK)

[†] To whom enquiries regarding X-ray crystallography should be addressed.

[**] TBADT = tetra-*n*-butylammonium decatungstate

Supporting information for this article is available on the WWW under <https://doi.org/10.1002/chem.202201478>

© 2022 The Authors. Chemistry - A European Journal published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

enones, as part of a larger investigation into the photochemistry of structurally modified morphine alkaloids.^[49] Herein, we describe the successful execution of this strategy.

Results and Discussion

This study began with attempts to functionalize enone **1a** with carbon-centered radicals using tetra-*n*-butylammonium decatungstate (TBADT) as the HAT photocatalyst (Figure 2).^[7,8] TBADT is one of the most versatile HAT photocatalysts, being able to generate radicals from C–H bonds at benzylic and allylic positions, α - to heteroatoms, and formyl groups, as well as at secondary or tertiary C–H bonds of simple alkyl groups.^[7] However, we were mindful that this very same versatility could present challenges of functional group incompatibility with a highly functionalized substrate such as **1a**, which contains several different types of C–H bonds that could also potentially react with TBADT (Figure 2). Nevertheless, investigating these issues of functional group tolerance are exactly the types of studies required to inform greater application of methods for late-stage modification of highly functionalized molecules.

An investigation of reaction conditions established that irradiation of a solution of **1a** and 3-phenylpropanal^[9] (5.0 equiv.) in MeCN (0.4 M concentration) in the presence of TBADT (5 mol%) at room temperature under argon for 16 h with blue LEDs gave the 1,4-addition product **2aa** in 67% isolated yield (Table 1, entry 1).^[10] The setting employed for the blue LED source has an emission spectrum with a small peak at ca. 390 nm (see Supporting Information for details). Changing the light source to a UV LED lamp (set at 370 nm, see Supporting Information for details) reduced the yield to 54% (Table 1, entry 2). Reducing the catalyst loading, reaction time, or concentration had detrimental effects on the yield (Table 1, entries 3–5). No reaction was observed in the absence of TBADT (Table 1, entry 6). Increasing the quantity of 3-phenylpropanal to 10.0 equiv. increased the yield to 74% (Table 1, entry 7), while using 2.0 equiv. resulted in a decreased yield of 43% (Table 1, entry 8). A reaction conducted under an air atmosphere gave essentially identical results (entry 9) to that conducted under argon (Table 1, entry 1). The inclusion of H₂O (10 equiv.) had a negative effect on the yield (Table 1, entry 10), while other HAT photocatalysts such as eosin Y^[11,12] and anthraquinone^[13] were ineffective, leading to significant recovered starting materials (Table 1, entries 11–13).

The conditions of Table 1, entry 1 were selected to explore the reaction of enone **1a** with other radical donors (Table 2).





Figure 2. C–H bonds in morphinan opioid **1a** with potential HAT reactivity.

Table 1. Evaluation of reaction conditions.^[a]


Entry	Deviation from Conditions	Yield of 2aa [%] ^[c]
1	None	67
2	UV lamp (370 nm)	54
3	1 mol% TBADT	32
4	Reaction time of 5 h	28
5	Concentration of 0.1 M	54
6	No TBADT	no reaction
7	Using 10.0 equiv. of 3-phenylpropanal	74
8	Using 2.0 equiv. of 3-phenylpropanal	43
9	In air	69
10	In presence of H ₂ O (10 equiv.)	42
11	Eosin Y (5 mol%) instead of TBADT	< 10 ^[d]
12	Anthraquinone (5 mol%)	< 10 ^[d]
13	Anthraquinone (5 mol%) with UV lamp (370 nm)	< 10 ^[d]

[a] Reactions were conducted using 0.30 mmol of **1a** in MeCN (0.75 M) under an argon atmosphere. [b] The blue LED source used has an emission spectrum with a small peak at ca. 390 nm (see Supporting Information for details). [c] Yield after isolation by column chromatography. [d] Only trace quantities of **2aa** were detected in the crude reaction mixture, which was not purified.

Other aliphatic aldehydes^[9] also reacted successfully to give **2ab–2ae**. In the case of 3-(benzyloxy)propanal, the reaction was sluggish and **2ac** was obtained in only 21% yield. The reaction was much more efficient using cyclohexanecarboxaldehyde, which gave **2ad** in 70% yield. This experiment also led to the formation of a small quantity of **2ak** (ca. 10%, not isolated) resulting from decarbonylation of the initially formed acyl radical and subsequent 1,4-addition.^[9a] Other acyl radical precursors such as 4-substituted benzaldehydes^[9] (**2af** and **2ag**), and formamide^[14] (**2ah**) also reacted successfully. Other radical precursors such as 1,3-benzodioxole (**2ai**)^[15,16] and cyclohexane (**2ka**) can also be employed. With DMF, C–H functionalization occurred at one of the methyl groups to give **2aj** in 31% yield. For **2ak**, 10 equiv. of cyclohexane were employed to achieve an acceptable yield. *tert*-Butyl methyl ether also reacted successfully to give **2al** in 34% yield when UV irradiation was employed, as no conversion was obtained using blue LEDs. Aside from the products, the remaining mass balance in these reactions consisted mostly of unreacted starting materials. Although the yields of some of these reactions are modest, the ability to modify a complex, highly functionalized substrate such as **1a** containing several potential competing sites of C–H functionalization (Figure 2) is notable. At present, there are relatively few such examples of TBADT-catalyzed functionalizations of highly functionalized molecules.^[17]

Table 2. Scope of radical precursors.^[a]


[a] Reactions were conducted using 0.30 mmol of **1a**. Yields are of isolated products. [b] The blue LED source used has an emission spectrum with a small peak at ca. 390 nm (see Supporting Information for details). [c] Approximately 10% of **2ak** was also detected in the crude reaction mixture. [d] Using 10 equiv. of cyclohexane. [e] Conducted in MeCN (0.75 mL) and DCE (0.20 mL) to increase solubility.

Table 3. Scope of opioid radical acceptor.^[a]

[a] Unless otherwise stated, reactions were conducted using 0.30 mmol of **1** in MeCN (3 mL). Yields are of isolated products. [b] The blue LED source used has an emission spectrum with a small peak at ca. 390 nm (see Supporting Information for details). [c] Conducted using 0.17 mmol of **1c**. [d] Conducted using 0.18 mmol of **1c**.

We next investigated the use of other morphinan opioids containing an enone in the C-ring and found that analogues of **1a** containing alternative protecting groups on the phenol (TBS; **2ba** or methyl; **2ca** and **2da**) and/or nitrogen atom (cyano; **2da**) reacted successfully with 3-phenylpropanal using blue LEDs to give products **2ba–2da** in 36–63% yield (Table 3). In addition, under UV irradiation, codeinone (**1e**) reacted with 3-phenylpropanal (**2ea**), 4-methoxybenzaldehyde (**2eg**), and 1,3-benzodioxole (**2ei**). Unfortunately, attempts to functionalize 14-hydroxycodeinone (**1f**) or enone **1g** using blue LEDs or UV irradiation were not successful, and gave mostly recovered starting materials. In the case of **1f**, poor solubility in MeCN may have been a contributing factor to the lack of reactivity.

The use of trimethylacetaldehyde as the radical precursor led to decarbonylation of the initially formed acyl radical to give a *tert*-butyl radical,^[9a] which added to enone **1a** to give **2am** in 79% yield (Scheme 1). An analogous reaction with codeinone (**1e**) gave **2em** in 38% yield. Interestingly, even though our previous attempts to functionalize enone **1g** failed



Scheme 1. Decarbonylative radical additions using trimethylacetaldehyde. [a] The blue LED source used has an emission spectrum with a small peak at ca. 390 nm (see Supporting Information for details).

(Table 3), **1g** reacted successfully with trimethylacetaldehyde under UV irradiation to give **2gm**, albeit in a modest 28% yield.

Finally, to demonstrate the removal of the ethoxycarbonyl groups present in many of the products to give native functionality present in opiates, **2am** was treated with sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al) (Scheme 2). This experiment resulted in deprotection of the carbonate to the free phenol, conversion of the carbamate to an *N*-methyl group, and stereoselective reduction of the ketone to give **3** in 71% yield.

Conclusion


In conclusion, we have reported the synthesis of new C8-functionalized morphinan opioids by the TBADT-catalyzed addition of photochemically generated carbon-centered radicals to substrates containing an enone in the morphinan C-ring. Despite the substrates containing several C–H bonds that could potentially react with TBADT, the products can be obtained in appreciable to good yields. This work demonstrates the power of late-stage functionalization in the modification of complex substrates for the preparation of novel analogues.

Acknowledgements

This work was supported by Navin Saxena Research & Technology through a PhD studentship to D. G., and the Engineering and Physical Sciences Research Council (EPSRC) and Science Foundation Ireland (SFI) Centre for Doctoral Training in Sustainable Chemistry [grant number EP/S022236/1] through a PhD studentship to E. S. We thank Rusan Pharma for providing starting materials used in this study. We thank Kevin Butler and Lola Ogunyemi for assistance with NMR spectroscopy.

Conflict of Interest

The authors declare no conflict of interest.



Scheme 2. Removal of the ethoxycarbonyl groups in **2am**.

Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article and at: <https://doi.org/10.17639/nott.7212>.

Keywords: late-stage functionalization · morphinans · opioids · photocatalysis · radical reactions

- [1] For reviews of the chemistry of morphine and related compounds, see: a) U. Rinner, T. Hudlicky, *Top. Curr. Chem.* **2012**, *309*, 33–66; b) T. Hudlicky, *Can. J. Chem.* **2015**, *93*, 492–501; c) J. W. Reed, T. Hudlicky, *Acc. Chem. Res.* **2015**, *48*, 674–687; d) S. A. Chambers, J. M. DeSousa, E. D. Huseman, S. D. Townsend, *ACS Chem. Neurosci.* **2018**, *9*, 2307–2330; e) A. L. Devereaux, S. L. Mercer, C. W. Cunningham, *ACS Chem. Neurosci.* **2018**, *9*, 2395–2407.
- [2] M. E. Olson, L. M. Eubanks, K. D. Janda, *J. Am. Chem. Soc.* **2018**, *141*, 1798–1806.
- [3] a) S. Furst, S. Hosztafi, *Acta Physiol. Hung.* **2008**, *95*, 3–44; b) A. P. Feinberg, I. Creese, S. H. Snyder, *Proc. Natl. Acad. Sci. USA* **1976**, *73*, 4215.
- [4] a) K. W. Bentley, D. G. Hardy, C. F. Howell, W. Fulmor, J. E. Lancaster, J. J. Brown, G. O. Morton, R. A. Hardy, *J. Am. Chem. Soc.* **1967**, *89*, 3303–3311; b) M. P. Kotick, D. L. Leland, J. O. Polazzi, R. N. Schut, *J. Med. Chem.* **1980**, *23*, 166–174; c) J. O. Polazzi, R. N. Schut, M. P. Kotick, J. F. Howes, P. F. Osgood, R. K. Razdan, J. E. Villarreal, *J. Med. Chem.* **1980**, *23*, 174–179; d) D. L. Leland, M. P. Kotick, *J. Med. Chem.* **1980**, *23*, 1427–1431; e) M. P. Kotick, *J. Med. Chem.* **1981**, *24*, 722–726; f) F. Ghosland, P. Maroni, I. Viloria, J. Cros, *Eur. J. Med. Chem.* **1983**, *18*, 22–26; g) A. G. Schultz, D. M. Graves, N. J. Green, R. R. Jacobson, D. M. Nowak, *J. Am. Chem. Soc.* **1994**, *116*, 10450–10462; h) H. Yu, T. Prisinzano, C. M. Dersch, J. Marcus, R. B. Rothman, A. E. Jacobson, K. C. Rice, *Bioorg. Med. Chem. Lett.* **2002**, *12*, 165–168; i) V. N. Kalinin, I. V. Shishkov, S. K. Moiseev, E. E. Shults, G. A. Tolstikov, N. I. Sosnina, P. V. Petrovskii, K. A. Lyssenko, H. Schmidhammer, *Helv. Chim. Acta* **2006**, *89*, 861–869; j) T. Kolev, R. Bakalska, R. W. Seidel, H. Mayer-Figge, I. M. Oettel, M. Spiteller, W. S. Sheldrick, B. B. Koleva, *Tetrahedron: Asymmetry* **2009**, *20*, 327–334.
- [5] For reviews of late-stage functionalization, see: a) T. Cernak, K. D. Dykstra, S. Tyagarajan, P. Vachal, S. W. Krska, *Chem. Soc. Rev.* **2016**, *45*, 546–576; b) M. C. White, J. P. Zhao, *J. Am. Chem. Soc.* **2018**, *140*, 13988–14009; c) M. Moir, J. J. Danon, T. A. Reekie, M. Kassiou, *Expert Opin. Drug Discovery* **2019**, *14*, 1137–1149; d) L. Capaldo, L. L. Quadri, D. Ravelli, *Green Chem.* **2020**, *22*, 3376–3396; e) L. Guillemand, N. Kaplaneris, L. Ackermann, M. J. Johansson, *Nat. Chem. Rev.* **2021**, *5*, 522–545; f) R. Cannalire, S. Pelliccia, L. Sancineto, E. Novellino, G. C. Tron, M. Giustiniano, *Chem. Soc. Rev.* **2021**, *50*, 766–897; g) S. K. Hota, D. Jinan, S. P. Panda, R. Pan, B. Sahoo, S. Murarka, *Asian J. Org. Chem.* **2021**, *10*, 1848–1860; h) J. D. Lasso, D. J. Castillo-Pazos, C.-J. Li, *Chem. Soc. Rev.* **2021**, *50*, 10955–10982.
- [6] For reviews covering HAT photocatalysis, see: a) L. Capaldo, D. Ravelli, *Eur. J. Org. Chem.* **2017**, 2056–2071; b) I. K. Sideri, E. Voutyritsa, C. G. Kokotos, *Org. Biomol. Chem.* **2018**, *16*, 4596–4614; c) M. A. Theodoropoulou, N. F. Nikitas, C. G. Kokotos, *Beilstein J. Org. Chem.* **2020**, *16*, 833–857; d) L. Capaldo, L. L. Quadri, D. Ravelli, *Green Chem.* **2020**, *22*, 3376–3396; e) H. Chen, S. Y. Yu, *Org. Biomol. Chem.* **2020**, *18*, 4519–4532; f) Z. Q. Ye, Y. M. Lin, L. Gong, *Eur. J. Org. Chem.* **2021**, 5545–5556; g) L. Capaldo, D. Ravelli, M. Fagnoni, *Chem. Rev.* **2022**, *122*, 1875–1924; h) M. Galeotti, M. Salamone, M. Bietti, *Chem. Soc. Rev.* **2022**, *51*, 2171–2223.
- [7] For reviews of TBADT, see: a) C. L. Hill, *Synlett* **1995**, 127–132; b) M. D. Tzirakis, I. N. Lykakis, M. Orfanopoulos, *Chem. Soc. Rev.* **2009**, *38*, 2609–2621; c) D. Ravelli, S. Protti, M. Fagnoni, *Acc. Chem. Res.* **2016**, *49*, 2232–2242; d) D. Ravelli, M. Fagnoni, T. Fukuyama, T. Nishikawa, I. Ryu, *ACS Catal.* **2018**, *8*, 701–713.
- [8] C. Lefebvre, T. Van Gysel, C. Michelin, E. Rousset, D. Djiré, F. Allais, N. Hoffmann, *Eur. J. Org. Chem.* **2022**, e202101298.
- [9] For examples of photocatalytic additions of acyl radicals to electron-deficient double bonds, see: a) S. Esposti, D. Dondi, M. Fagnoni, A. Albini, *Angew. Chem. Int. Ed.* **2007**, *46*, 2531–2534; *Angew. Chem.* **2007**, *119*, 2583–2586; b) D. Ravelli, M. Zema, M. Mella, M. Fagnoni, A. Albini, *Org. Biomol. Chem.* **2010**, *8*, 4158–4164; c) D. Ravelli, S. Montanaro, M.


- Zema, M. Fagnoni, A. Albini, *Adv. Synth. Catal.* **2011**, *353*, 3295–3300; d) M. D. Vu, M. Das, X.-W. Liu, *Chem. Eur. J.* **2017**, *23*, 15899–15902; e) G. N. Papadopoulos, E. Voutyritsa, N. Kaplaneris, C. G. Kokotos, *Chem. Eur. J.* **2018**, *24*, 1726–1731; f) G. Goti, B. Bieszczad, A. Vega-Peñaloza, P. Melchiorre, *Angew. Chem. Int. Ed.* **2019**, *58*, 1213–1217; *Angew. Chem.* **2019**, *131*, 1226–1230; g) T. Morack, C. Mück-Lichtenfeld, R. Gilmour, *Angew. Chem. Int. Ed.* **2019**, *58*, 1208–1212; *Angew. Chem.* **2019**, *131*, 1221–1225; h) E. Voutyritsa, C. G. Kokotos, *Angew. Chem. Int. Ed.* **2020**, *59*, 1735–1741; *Angew. Chem.* **2020**, *132*, 1752–1758; i) N. Spiliopoulou, P. L. Gkizis, I. Triandafillidi, N. F. Nikitas, C. S. Batsika, A. Bisticha, C. G. Kokotos, *Chem. Eur. J.* **2022**, *28*, e202200023.
- [10] The absolute configuration of the newly created C8 stereocenter of **2aa** was confirmed by X-ray crystallography and the stereochemical outcomes of the remaining reactions were confirmed by analogy. Deposition Number(s) 2149928 contain(s) the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service.
- [11] a) X.-Z. Fan, J.-W. Rong, H.-L. Wu, Q. Zhou, H.-P. Deng, J. D. Tan, C.-W. Xue, L.-Z. Wu, H.-R. Tao, J. Wu, *Angew. Chem. Int. Ed.* **2018**, *57*, 8514–8518; *Angew. Chem.* **2018**, *130*, 8650–8654; b) Y. Kuang, K. Wang, X. Shi, X. Huang, E. Meggers, J. Wu, *Angew. Chem. Int. Ed.* **2019**, *58*, 16859–16863; *Angew. Chem.* **2019**, *131*, 17015–17019.
- [12] For reviews on eosin Y, see: a) D. P. Hari, B. König, *Chem. Commun.* **2014**, *50*, 6688–6699; b) M. Majek, F. Filace, A. J. v. Wangelin, *Beilstein J. Org. Chem.* **2014**, *10*, 981–989; c) V. Srivastava, P. P. Singh, *RSC Adv.* **2017**, *7*, 31377–31392.
- [13] J. Cervantes-González, D. A. Vosburg, S. E. Mora-Rodriguez, M. A. Vázquez, L. G. Zepeda, C. Villegas Gómez, S. Lagunas-Rivera, *ChemCatChem* **2020**, *12*, 3811–3827.
- [14] S. Angioni, D. Ravelli, D. Emma, D. Dondi, M. Fagnoni, A. Albini, *Adv. Synth. Catal.* **2008**, *350*, 2209–2214.
- [15] D. Ravelli, A. Albini, M. Fagnoni, *Chem. Eur. J.* **2011**, *17*, 572–579.
- [16] For selected examples of other photocatalytic additions of heterocycles to electron-deficient alkenes, see Ref. [11a] and a) J. B. McManus, N. P. R. Onuska, D. A. Nicewicz, *J. Am. Chem. Soc.* **2018**, *140*, 9056–9060; b) S. Rohe, A. O. Morris, T. McCallum, L. Barriault, *Angew. Chem. Int. Ed.* **2018**, *57*, 15664–15669; *Angew. Chem.* **2018**, *130*, 15890–15895; c) G. N. Papadopoulos, M. G. Kokotou, N. Spiliopoulou, N. F. Nikitas, E. Voutyritsa, D. I. Tzaras, N. Kaplaneris, C. G. Kokotos, *ChemSusChem* **2020**, *13*, 5934–5944.
- [17] a) S. D. Halperin, H. Fan, S. Chang, R. E. Martin, R. Britton, *Angew. Chem. Int. Ed.* **2014**, *53*, 4690–4693; *Angew. Chem.* **2014**, *126*, 4778–4781; b) M. B. Nodwell, H. Yang, M. Čolović, Z. Yuan, H. Merckens, R. E. Martin, F. Bénard, P. Schaffer, R. Britton, *J. Am. Chem. Soc.* **2017**, *139*, 3595–3598; c) C. R. Zwick, H. Renata, *J. Am. Chem. Soc.* **2018**, *140*, 1165–1169; d) G. Laudadio, S. Govaerts, Y. Wang, D. Ravelli, H. F. Koolman, M. Fagnoni, S. W. Djuric, T. Noël, *Angew. Chem. Int. Ed.* **2018**, *57*, 4078–4082; *Angew. Chem.* **2018**, *130*, 4142–4146; e) Z. Yuan, M. B. Nodwell, H. Yang, N. Malik, H. Merckens, F. Bénard, R. E. Martin, P. Schaffer, R. Britton, *Angew. Chem. Int. Ed.* **2018**, *57*, 12733–12736; *Angew. Chem.* **2018**, *130*, 12915–12918; f) H. Cao, Y. Kuang, X. Shi, K. L. Wong, B. B. Tan, J. M. C. Kwan, X. Liu, J. Wu, *Nat. Commun.* **2020**, *11*, 1956; g) J. Dong, F. Yue, X. Wang, H. Song, Y. Liu, Q. Wang, *Org. Lett.* **2020**, *22*, 8272–8277; h) M. Kleoff, J. Schwan, M. Christmann, P. Heretsch, *Org. Lett.* **2021**, *23*, 2370–2374; i) T. Wan, L. Capaldo, G. Laudadio, A. V. Nyuchev, J. A. Rincón, P. García-Losada, C. Mateos, M. O. Frederick, M. Nuño, T. Noël, *Angew. Chem. Int. Ed.* **2021**, *60*, 17893–17897.

Manuscript received: May 13, 2022

Accepted manuscript online: June 5, 2022

Version of record online: ■■■, ■■■■

RESEARCH ARTICLE



The synthesis of new morphinan opioids by the addition of photochemically generated carbon-centered radicals to substrates containing an enone in the morphinan C-ring, is described. Using tetrabutylammonium decatungstate (TBADT) as a

hydrogen atom transfer photocatalyst, diverse radical donors can be used to prepare a variety of C8-functionalized morphinan opioids. This work demonstrates the late-stage modification of complex, highly functionalized substrates.

*D. Gorbachev, E. Smith, Dr. S. P. Argent, Dr. G. N. Newton, Prof. H. W. Lam**

1 – 6

Synthesis of New Morphinan Opioids by TBADT-Catalyzed Photochemical Functionalization at the Carbon Skeleton

